Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Inclusion Criteria Patients may be eligible for this study if they: * Are at least 13 years old. * Are HIV-positive. * Have a viral load of at least 5,000 copies/ml. * Agree to use adequate and reliable methods of birth control. Note: Hormonal birth control is not considered adequate. * Provide written consent of a parent or guardian, if under 18 years of age. Exclusion Criteria Patients will not be eligible for this study if they: * Have taken nonnucleoside reverse transcriptase inhibitors. * Have taken other anti-HIV drugs for 2 weeks or more. * Have an opportunistic (AIDS-related) infection. * Are pregnant or breast-feeding. * Have had hepatitis within the past 6 months. * Are allergic to the study drugs or their ingredients. * Have a mental, physical, or substance abuse disorder. * Have a serious medical condition, such as diabetes, congestive heart failure, or other heart disease. * Have a gastrointestinal disorder that affects drug absorption or makes it difficult to take medication by mouth. * Have received within 4 weeks before study entry, or may require during the study period, radiation therapy, chemotherapy, or drugs that affect the immune system (such as steroid drugs, interleukins, vaccines, or interferons). * Have received an HIV vaccine within 3 months before study entry, or are scheduled to receive one during the study period. * Require foscarnet or other drugs that are shown to be effective against HIV. * Are taking astemizole, cisapride, midazolam, triazolam, or ergot derivatives. * Are taking experimental drugs. * Are unlikely to complete the study or take the drugs.